Conclusion
This study emphasis that diffuse alveolar damage and microvascular pulmonary thrombosis in SARS-CoV-2 patients caused by either direct viral cytopathic effect or host immune and inflammatory reaction. Due to severe hypoxemia in COVID-19 patients suffering ARDS, appropriate oxygen support and anticoagulation therapy with strict monitoring is recommended.
Key words: COVID-19, diffuse alveolar damage, biopsy, thrombosis